CD25 x CTLA-4 bispecific DART molecule(MacroGenics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCD25 x CTLA-4 bispecific DART molecule(MacroGenics)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes inhibitorsCD8-positive T-Lymphocytes stimulants +[4]

TargetsCytotoxic T-Lymphocyte-Associated Antigen 4

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMacrogenics Inc

China Registration ClassN/A

Active CompaniesMacrogenics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

ATC CodeN/A